PMC:7195088 / 15278-15640 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"734","span":{"begin":152,"end":171},"obj":"Chemical"}],"attributes":[{"id":"A734","pred":"tao:has_database_id","subj":"734","obj":"MESH:C558899"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ality (19.2% vs. 25.0% in investigational and comparator arms, respectively; percentage difference −5.8%, 95% CI −17.3 to 5.7). In the mITT population, lopinavir/ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care. Median time between symptoms onset and randomization was 13 days (IQR 11–16) [22"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T52","span":{"begin":57,"end":61},"obj":"http://www.ebi.ac.uk/efo/EFO_0001410"},{"id":"T53","span":{"begin":179,"end":180},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T54","span":{"begin":352,"end":354},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T55","span":{"begin":360,"end":362},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"}],"text":"ality (19.2% vs. 25.0% in investigational and comparator arms, respectively; percentage difference −5.8%, 95% CI −17.3 to 5.7). In the mITT population, lopinavir/ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care. Median time between symptoms onset and randomization was 13 days (IQR 11–16) [22"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T84","span":{"begin":152,"end":171},"obj":"Chemical"},{"id":"T85","span":{"begin":152,"end":161},"obj":"Chemical"},{"id":"T86","span":{"begin":162,"end":171},"obj":"Chemical"}],"attributes":[{"id":"A84","pred":"chebi_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A85","pred":"chebi_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A86","pred":"chebi_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"}],"text":"ality (19.2% vs. 25.0% in investigational and comparator arms, respectively; percentage difference −5.8%, 95% CI −17.3 to 5.7). In the mITT population, lopinavir/ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care. Median time between symptoms onset and randomization was 13 days (IQR 11–16) [22"}

{"project":"LitCovid-sentences","denotations":[{"id":"T95","span":{"begin":128,"end":281},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ality (19.2% vs. 25.0% in investigational and comparator arms, respectively; percentage difference −5.8%, 95% CI −17.3 to 5.7). In the mITT population, lopinavir/ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care. Median time between symptoms onset and randomization was 13 days (IQR 11–16) [22"}

{"project":"2_test","denotations":[{"id":"32360444-32187464-22369752","span":{"begin":360,"end":362},"obj":"32187464"}],"text":"ality (19.2% vs. 25.0% in investigational and comparator arms, respectively; percentage difference −5.8%, 95% CI −17.3 to 5.7). In the mITT population, lopinavir/ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care. Median time between symptoms onset and randomization was 13 days (IQR 11–16) [22"}